Stemline Therapeutics Inc (NASDAQ:STML) Receives $25.00 Consensus Target Price from Analysts

Shares of Stemline Therapeutics Inc (NASDAQ:STML) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.00.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several analysts have recently commented on STML shares. Zacks Investment Research cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stemline Therapeutics in a report on Monday, September 30th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. Finally, Wedbush upgraded Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a report on Friday, August 2nd.

Shares of NASDAQ STML traded down $1.19 during trading hours on Tuesday, reaching $9.25. The stock had a trading volume of 2,655,100 shares, compared to its average volume of 625,907. The business’s fifty day moving average is $9.85 and its two-hundred day moving average is $12.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.57. The company has a market cap of $486.37 million, a price-to-earnings ratio of -3.09 and a beta of 1.35. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $18.22.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. The business had revenue of $13.33 million for the quarter, compared to the consensus estimate of $13.40 million. Sell-side analysts forecast that Stemline Therapeutics will post -1.99 earnings per share for the current fiscal year.

In related news, CEO Ivan Bergstein sold 35,010 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $14.73, for a total value of $515,697.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 13.10% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Stemline Therapeutics by 51.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 1,466 shares during the last quarter. Bank of Montreal Can bought a new position in Stemline Therapeutics in the second quarter valued at about $52,000. Steward Partners Investment Advisory LLC bought a new position in Stemline Therapeutics in the second quarter valued at about $67,000. Tower Research Capital LLC TRC boosted its holdings in Stemline Therapeutics by 364.4% in the third quarter. Tower Research Capital LLC TRC now owns 7,115 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 5,583 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Stemline Therapeutics in the second quarter valued at about $104,000. Institutional investors and hedge funds own 83.00% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Why do companies engage in swaps?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Leave a Reply

Your email address will not be published. Required fields are marked *

*